Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs VanEck Vietnam ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while VanEck Vietnam ETF trades at $16.38 (market cap $465.30M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is far larger — about 2.1× VanEck Vietnam ETF's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and VanEck Vietnam ETF for 52 Days on average.
| MRVI | VNM | |
|---|---|---|
Market Cap | $972.90M | $465.30M |
Volume | 4,325,710 | 633,123 |
Sector | Health | Sector/Thematic |
52-Week High | $9.00 | $19.80 |
52-Week Low | $2.83 | $16.34 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
VNM stock trades at $16.53, down 0.3% with a bearish technical signal from moving averages. The ETF faces sector concentration risks in real estate and financials while trading at fair valuation. Recent news highlights Vietnam's potential US trade deal progress, though the fund has underperformed despite country growth prospects.
Near-term outlook remains cautious due to technical weakness and sector headwinds. Long-term exposure to Vietnam's growth offers potential, but investors face volatility from interest rate sensitivity and concentrated sector risks. The bearish technical setup suggests continued pressure on current price levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
